5aau: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='5aau' size='340' side='right'caption='[[5aau]], [[Resolution|resolution]] 1.90Å' scene=''> | <StructureSection load='5aau' size='340' side='right'caption='[[5aau]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5aau]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[5aau]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AAU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AAU FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=XBR:3-(1-(4-CHLOROPHENYL)-3,4-DIHYDRO-1H-PYRIDO(3,4-B)INDOL-2(9H)-YL)PROPANOIC+ACID'>XBR</scene> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XBR:3-(1-(4-CHLOROPHENYL)-3,4-DIHYDRO-1H-PYRIDO(3,4-B)INDOL-2(9H)-YL)PROPANOIC+ACID'>XBR</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5aau FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5aau OCA], [https://pdbe.org/5aau PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5aau RCSB], [https://www.ebi.ac.uk/pdbsum/5aau PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5aau ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/ESR1_HUMAN ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.<ref>PMID:7651415</ref> <ref>PMID:10970861</ref> <ref>PMID:9328340</ref> <ref>PMID:10681512</ref> <ref>PMID:10816575</ref> <ref>PMID:11477071</ref> <ref>PMID:11682626</ref> <ref>PMID:15078875</ref> <ref>PMID:16043358</ref> <ref>PMID:15891768</ref> <ref>PMID:16684779</ref> <ref>PMID:18247370</ref> <ref>PMID:17932106</ref> <ref>PMID:19350539</ref> <ref>PMID:20705611</ref> <ref>PMID:21937726</ref> <ref>PMID:21330404</ref> <ref>PMID:22083956</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 26: | Line 25: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Andrews DM]] | |||
[[Category: Andrews | [[Category: Ballard P]] | ||
[[Category: Ballard | [[Category: Bradbury RH]] | ||
[[Category: Bradbury | [[Category: Buttar D]] | ||
[[Category: Buttar | [[Category: Callis RJ]] | ||
[[Category: Callis | [[Category: Currie GS]] | ||
[[Category: Currie | [[Category: Curwen JO]] | ||
[[Category: Curwen | [[Category: Davies CD]] | ||
[[Category: Davies | [[Category: Donald CS]] | ||
[[Category: Donald | [[Category: Feron LJL]] | ||
[[Category: Feron | [[Category: Glossop SC]] | ||
[[Category: Glossop | [[Category: Hayter BR]] | ||
[[Category: Hayter | [[Category: Karoutchi G]] | ||
[[Category: Karoutchi | [[Category: Lamont SG]] | ||
[[Category: Lamont | [[Category: MacFaul P]] | ||
[[Category: MacFaul | [[Category: Moss T]] | ||
[[Category: Moss | [[Category: Norman RA]] | ||
[[Category: Norman | [[Category: Pearson SE]] | ||
[[Category: Pearson | [[Category: Rabow AA]] | ||
[[Category: Rabow | [[Category: Tonge M]] | ||
[[Category: Walker GE]] | |||
[[Category: Tonge | [[Category: Weir HM]] | ||
[[Category: Walker | [[Category: Wilson Z]] | ||
[[Category: Weir | [[Category: De Almeida C]] | ||
[[Category: Wilson | [[Category: De Savi C]] | ||
[[Category: | |||
[[Category: | |||
Revision as of 04:48, 25 May 2023
Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist
| ||||||||||||